* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Adam Koppel
Managing Dir. of Bain Capital Life Sciences Investors, LLC
Boston, Massachusetts
2/14/2022
Bain Capital Life Sciences Investors, LLC is (i) the general partner of Bain Capital Life Sciences Partners, LP, which is the general partner of Bain Capital Life Sciences Fund, L.P., (ii) the general partner of BC SW, LP and (iii) the manager of Bain Capital Life Sciences Investors II, LLC, which is the general partner of Bain Capital Life Sciences Fund II, L.P. Bain Capital Life Sciences Investors, LLC governs the investment strategy and decision-making process with respect to investments held by BCIP Life Sciences Associates, LP. The shares of common stock of Savara Inc ("SVRA") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13D filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on March 17, 2021 and reflect the exercise of securities exercisable for shares of SVRA common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SVRA common stock following such exercise. As of December 31, 2021, such persons held an aggregate of 6,913,208 shares of SVRA common stock. The shares of common stock of Syros Pharmaceuticals, Inc. ("SYRS" ) included on the Information Table are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences Fund II, L.P. and BCIP Life Sciences Associates, LP on February 14, 2022 and reflect the exercise of securities exercisable for shares of SYRS common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding SYRS common stock following such exercise. As of December 31, 2021, such persons held an aggregate of 5,504,661 shares of SYRS common stock. The shares of common stock of X4 Pharmaceuticals, Inc. ("XFOR") included on the Information Table are as reported on Amendment No. 1 to the Schedule 13G filed by Bain Capital Life Sciences, L.P., Bain Capital Life Sciences Fund II, L.P., BCLS II Investco, LP and BCIP Life Sciences Associates, LP on February 14, 2022 and reflect the exercise of securities exercisable for shares of XFOR common stock held by such persons, after giving effect to the provisions of such securities that prevent the exercise of such securities if such persons would beneficially own more than 9.99% of the outstanding XFOR common stock following such exercise. As of December 31, 2021, such persons held an aggregate of 2,119,540 shares of XFOR common stock.
Other Included Managers (6):
Num
Name
File Number
1
Bain Capital Life Sciences Partners, LP
028-18476
2
Bain Capital Life Sciences Fund, L.P.
028-18478
3
BC SW, LP
028-20270
4
Bain Capital Life Sciences Investors II, LLC
028-20816
5
Bain Capital Life Sciences Fund II, L.P.
028-20814
6
BCIP Life Sciences Associates, LP
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.